Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Next Previous
Trial Profile

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Non-radiographic axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-axSpA
  • Sponsors UCB; UCB Biosciences

    • Most Recent Events

    • 03 Jun 2023 Results of post hoc analysis assessing relationship between objective signs of inflammation (OSI), as measured by MRI/CRP, and clinical outcomes following 12 weeks of CZP treatment in pts with active axSpA presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results of post hoc analysis assessing relationship between objective signs of inflammation as measured by MRI/CRP and clinical outcomes presented at the ACR Convergence 2022
    • 15 Nov 2021 Results of post-hoc sub-study assessing whether TNFi treatment over 4 years impacts fat lesions in spinal vertebral edges in patients with axSpA stratified by axSpA subpopulation (r-axSpA/nr-axSpA) or disease duration years published in the Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top